Drug Approval | July 22, 2024
Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
Subscribe To Our Newsletter & Stay Updated
